Pernicious anemia is diagnosed through a layered set of blood tests rather than a single definitive marker. The process typically starts with a complete blood count and a serum vitamin B12 level, then moves to metabolic markers like methylmalonic acid and homocysteine, and finally to antibody tests that identify the autoimmune cause. What makes diagnosis tricky is that several of these individual tests can appear normal even when the disease is present, so clinicians often need to run the full panel before reaching a confident answer.
What Pernicious Anemia Actually Is
Pernicious anemia is a specific type of vitamin B12 deficiency caused by an autoimmune attack on the stomach lining. The immune system targets the parietal cells of the stomach, which are responsible for producing intrinsic factor, a protein you need to absorb B12 from food. Without intrinsic factor, dietary B12 passes through your gut unabsorbed, and your body’s stores slowly deplete over months to years.1PubMed. Pathophysiology and laboratory diagnosis of pernicious anemia The “pernicious” label dates from an era when the condition was fatal, but today it is manageable with B12 supplementation, usually by injection, once recognized.
The distinction matters because not all B12 deficiency is pernicious anemia. Poor diet, malabsorption from gut surgery, celiac disease, and certain medications can all drive B12 levels down. Pernicious anemia specifically involves the autoimmune destruction of parietal cells and the resulting loss of intrinsic factor.2PubMed Central. Pernicious anemia: new insights from a gastroenterological point of view That autoimmune component is what the diagnostic workup is ultimately trying to confirm.
Step One: The Complete Blood Count
A standard complete blood count (CBC) is usually where suspicion begins. The textbook picture of pernicious anemia is a macrocytic anemia: low hemoglobin (indicating anemia) combined with a high mean corpuscular volume, or MCV (indicating abnormally large red blood cells). In advanced cases, you might also see low white blood cell or platelet counts. A peripheral blood smear can reveal oval-shaped macrocytes and hypersegmented neutrophils, which are considered a hallmark of B12 deficiency.3PubMed Central. Hypersegmented neutrophils and oval macrocytes in the setting of B12 deficiency and pancytopaenia
Here is where the first major pitfall comes in: a surprisingly large number of people with confirmed pernicious anemia do not have the classic CBC findings. In a review of 100 consecutive patients with confirmed disease, only about two-thirds had an MCV above 100 fL, and roughly 29% had a hemoglobin below 12 g/dL.4Mayo Clinic Proceedings. Pernicious Anemia Revisited Another study found that anemia was absent in about one in five patients and macrocytosis was absent in a third, particularly when B12 levels were only mildly or moderately low rather than profoundly depleted.5JAMA Internal Medicine. Pernicious Anemia: The Expected Findings of Very Low Serum Cobalamin Levels, Anemia, and Macrocytosis Are Often Lacking If you rely solely on a CBC to screen for pernicious anemia, you will miss a meaningful chunk of cases.
Serum B12 and Its Limitations
A serum B12 level is the standard first-line test when deficiency is suspected. Most labs set the deficiency threshold at roughly 200 pg/mL (about 148 pmol/L), though exact cutoffs vary by laboratory and assay platform.6PubMed. Laboratory assessment of vitamin B12 status A clearly low result in someone with suggestive symptoms raises the question of why B12 is low, which then prompts the antibody tests discussed below.
The problem is that serum B12 is a blunt instrument. The standard assay measures total B12 in blood, which includes both the form bound to a transport protein called haptocorrin (metabolically inactive) and the form bound to transcobalamin (the only form cells actually use). Someone can have a “normal” total B12 while the biologically active fraction is inadequate.6PubMed. Laboratory assessment of vitamin B12 status There is also a specific concern with pernicious anemia: the anti-intrinsic factor antibodies present in these patients can interfere with the competitive-binding assays used to measure B12, producing falsely normal results even when the patient is profoundly deficient.7PubMed. False-normal vitamin B12 results in a patient with pernicious anaemia When clinical suspicion is high but the B12 level looks reassuring, the workup should not stop there.
A newer option is holotranscobalamin (sometimes called “active B12”), which measures only the biologically available fraction. Studies suggest it is somewhat more sensitive and specific than total B12.8PubMed Central. Diagnostic reliability of serum active B12 (holo-transcobalamin) in true evaluation of vitamin B12 deficiency: Relevance in current perspective It is not yet universally available, but when it is offered, it can be a useful add-on, especially in ambiguous cases where total B12 sits in the indeterminate zone between clearly normal and clearly deficient.
Metabolic Markers That Reveal Hidden Deficiency
When the serum B12 is borderline or falsely normal, two metabolic markers can expose the deficiency at the cellular level: methylmalonic acid (MMA) and homocysteine. Both accumulate in the blood when B12 is insufficient, because the body cannot complete certain enzymatic reactions without it. MMA rises specifically in B12 deficiency, while homocysteine rises in both B12 and folate deficiency, making MMA the more targeted of the two.
These markers are remarkably sensitive. In a large series of confirmed B12-deficient patients, MMA was elevated in over 98% and homocysteine in about 96% of cases. Only one patient in the entire series had normal levels of both metabolites.9The American Journal of Medicine. Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies That kind of sensitivity makes MMA especially valuable as a tiebreaker: if MMA is elevated, a functional B12 shortage is almost certainly present regardless of what the total serum B12 number says.
There is an important caveat. Among patients whose serum B12 appeared sufficient (above 300 pg/mL), roughly one in five had an elevated MMA or homocysteine level suggesting that B12 was not actually adequate at the tissue level.10PubMed Central. Methylmalonic Acid and Homocysteine as Indicators of Vitamin B-12 Deficiency in Cancer This reinforces a practical message: using serum B12 alone as the gatekeeper for deficiency means missing a real fraction of people who would benefit from treatment. Many clinicians now order MMA reflexively whenever B12 is low-normal, or whenever there is a strong clinical reason to suspect deficiency despite a “normal” B12.
One limitation of MMA is that it also rises in kidney disease, so an elevated MMA in someone with impaired kidney function needs to be interpreted cautiously. Homocysteine is similarly nonspecific because it rises with folate deficiency, hypothyroidism, and kidney problems. Neither marker alone proves that pernicious anemia is the cause of the deficiency. They confirm the deficiency exists; the antibody tests then point to why.
Anti-Intrinsic Factor Antibodies: The Most Specific Test
Once B12 deficiency is established (by low serum B12, elevated MMA, or both), the next step is determining whether the cause is pernicious anemia. The test most specific for this is the anti-intrinsic factor antibody (IFA). A positive result in the context of confirmed B12 deficiency is considered diagnostic. Specificity across commercial assays runs between 76% and 100%, with most platforms at the higher end.11PubMed. Comparison of different immunoassays for the detection of antibodies against Intrinsic Factor and Parietal Cells
The tradeoff is sensitivity. Not every patient with pernicious anemia produces detectable levels of anti-intrinsic factor antibodies. Across different assay platforms, sensitivity for IFA ranges from about 85% to 100%, meaning some patients with genuine autoimmune-driven disease will test negative.11PubMed. Comparison of different immunoassays for the detection of antibodies against Intrinsic Factor and Parietal Cells A positive result essentially clinches the diagnosis. A negative result does not rule it out.
Anti-Parietal Cell Antibodies: Sensitive but Blurry
Anti-parietal cell antibodies (APCA) are the other commonly ordered autoantibody. They are found in about 90% of people with pernicious anemia, making them quite sensitive.12PubMed. Diagnosis and classification of pernicious anemia The trouble is that they also show up in people with atrophic gastritis who never develop pernicious anemia, and in people with other autoimmune conditions entirely. Their poor specificity raises real concerns about overdiagnosis if used in isolation.13PubMed. Not all anti-parietal cell antibody tests are equal for diagnosing pernicious anemia
In practice, APCA are most useful when combined with the intrinsic factor antibody. A patient with low B12, elevated MMA, and positive IFA has a clear diagnosis. A patient with low B12, elevated MMA, positive APCA but negative IFA has a strong but not airtight case, and further evaluation (gastric biopsies, pepsinogen levels) may be warranted. Running APCA alone without the more specific IFA test is a common mistake that can lead to both false reassurance and false alarms.
Pepsinogen, Gastrin, and Other Gastric Markers
Because pernicious anemia stems from autoimmune destruction of the stomach’s parietal cells, the damage leaves a biochemical fingerprint in blood markers related to gastric function. Two pepsinogen proteins, PG I and PG II, and the hormone gastrin are the most studied.
Parietal cell loss causes PG I to drop (because PG I is produced in the gastric body where parietal cells live) while PG II stays relatively steady. A low PG I level or a low PG I-to-PG II ratio is a sensitive indicator of the corpus atrophy that underlies pernicious anemia. In one study, a PG I below 30 micrograms per liter was found in 92% of pernicious anemia patients, and when combined with the PG I-to-PG II ratio, at least one of these two markers was abnormal in 97% of cases. Elevated gastrin, which rises when the stomach loses acid-producing capacity, was found in 90% of patients.14PubMed. Pepsinogens and other serum markers in pernicious anemia The pepsinogen findings were even more sensitive than antibody results in that study, making them especially useful when antibodies are negative but suspicion remains high.
Pepsinogen testing is widely available in some countries (it is used routinely for gastric cancer screening in parts of East Asia) but underutilized in others. If your clinician has not considered it and antibody results are ambiguous, it is worth asking about.
When Endoscopy Becomes Necessary
Blood tests can strongly suggest pernicious anemia, but endoscopy with biopsy gives the most definitive picture of what is happening in the stomach. An upper endoscopy lets the gastroenterologist look directly at the stomach lining for visible signs of atrophy, and biopsies from different regions of the stomach can confirm the pattern of corpus-predominant atrophic gastritis that defines the disease.
The American Gastroenterological Association recommends that patients with a new diagnosis of pernicious anemia who have not had a recent endoscopy undergo one. The purpose is twofold: to confirm the atrophic gastritis histologically and to screen for gastric neoplasia, including neuroendocrine tumors, which are more common in pernicious anemia patients. Biopsies should be taken from both the body and antrum of the stomach and placed in separate containers so the pathologist can map the distribution of atrophy.15PubMed Central. AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review
Endoscopy is not required to start B12 treatment, which should begin as soon as deficiency is confirmed. But it provides crucial risk-stratification information. The extent and severity of gastric atrophy determines follow-up surveillance intervals and your long-term risk of gastric cancer.
A Practical Diagnostic Sequence
Putting the pieces together, most experts describe a stepwise approach. The initial screen is serum B12 (or holotranscobalamin where available). If it is low or in the indeterminate range, or if clinical suspicion is strong even with a normal result, MMA is checked to confirm functional deficiency at the tissue level. Once deficiency is confirmed, the intrinsic factor antibody is tested to identify pernicious anemia as the underlying cause. Anti-parietal cell antibodies, pepsinogen levels, and gastrin can add supporting evidence, especially when the IFA is negative.16Discovery Medicine. Advances in Mechanisms, Diagnosis, and Treatment of Pernicious Anemia Endoscopy follows to characterize the stomach damage and rule out neoplasia.
One challenge in real-world practice is that this sequence does not always unfold neatly. A patient may present with neurological symptoms and no anemia at all. A serum B12 may come back falsely normal. An IFA may be negative in someone who clearly has the disease. The layered approach exists precisely because no single test is both sensitive and specific enough to stand alone.
Neurological Symptoms Without Anemia
One of the most dangerous diagnostic pitfalls is the assumption that pernicious anemia must involve anemia. Neurological and psychiatric symptoms, including numbness and tingling in the hands and feet, balance problems, cognitive impairment, depression, and in severe cases, damage to the spinal cord called subacute combined degeneration, can appear before any blood count abnormality develops.17PubMed Central. Pernicious Anemia: Basic Pathophysiology and Diagnostic Challenges in Neuropsychiatric Patients Because the name of the disease contains the word “anemia,” clinicians sometimes dismiss B12 deficiency when the hemoglobin is fine. But the nervous system can sustain damage at B12 levels that are not yet low enough to impair red blood cell production.
This pattern of neurological presentation without hematologic changes is well-documented, and it contributes to delayed diagnosis that can stretch for years.18PubMed Central. A long-standing undiagnosed case of vitamin B12 deficiency: a case report The takeaway is straightforward: if you or your doctor suspect B12 deficiency based on neurological symptoms, a normal CBC should not end the investigation. Serum B12, MMA, and antibody testing should proceed regardless.
Drug-Induced B12 Deficiency Versus Pernicious Anemia
Before attributing B12 deficiency to pernicious anemia, it is worth considering whether medications might be the cause. Two drug classes are well-documented culprits: metformin (used for type 2 diabetes) and proton pump inhibitors, or PPIs (used for acid reflux). Both can lower B12 absorption through mechanisms that have nothing to do with autoimmune gastritis. Metformin appears to interfere with calcium-dependent B12 absorption in the small intestine, while PPIs suppress stomach acid, which is needed to release B12 from food proteins.
The combination of metformin and a PPI carries a higher risk of B12 deficiency than either drug alone.19PubMed Central. Concomitant use of metformin and proton pump inhibitors increases vitamin B12 deficiency risk in type 2 diabetes Both drugs and all common PPIs have been associated with elevated reporting of B12 deficiency in pharmacovigilance analyses.20PubMed Central. Vitamin B12 Deficiency Associated with Metformin and Proton Pump Inhibitors and Their Combinations: Results from a Disproportionality and Interaction Analysis If you are on one or both of these medications and your B12 comes back low, the antibody tests become critical: a negative IFA and APCA would point toward drug-induced deficiency rather than pernicious anemia, changing both the treatment plan and the monitoring schedule.
Autoimmune Conditions That Travel Together
Pernicious anemia rarely exists in isolation. Because it is autoimmune in nature, it clusters with other autoimmune diseases, and recognizing these associations can prompt earlier testing. The most common companion is autoimmune thyroid disease, particularly Hashimoto’s thyroiditis. In one retrospective study, the most frequent pairing was pernicious anemia with autoimmune thyroiditis, seen in 30 cases of a syndrome grouping, sometimes joined by type 1 diabetes, vitiligo, or myasthenia gravis.21PubMed Central. Association pernicious anemia and autoimmune polyendocrinopathy: a retrospective study
Among people with type 1 diabetes specifically, an estimated 5% to 10% develop autoimmune gastritis or pernicious anemia.22PubMed Central. A case report on autoimmune polyglandular syndrome type 2 with pernicious anemia These overlapping conditions fall under what is sometimes called autoimmune polyglandular syndrome, which can involve combinations of Addison’s disease (adrenal insufficiency), thyroid disorders, type 1 diabetes, and pernicious anemia.23PubMed Central. Shock: A possible presenting manifestation of autoimmune polyendocrine syndrome type II If you already have one autoimmune condition, particularly thyroid disease or type 1 diabetes, periodic screening for B12 deficiency is reasonable even if you feel well.
Hereditary Intrinsic Factor Deficiency
There is a rare hereditary condition that mimics pernicious anemia but follows an entirely different mechanism. In hereditary intrinsic factor deficiency, mutations in the gene encoding intrinsic factor (GIF, on chromosome 11) prevent the body from producing functional intrinsic factor from birth. The result is the same, B12 cannot be absorbed, but the cause is genetic rather than autoimmune, and autoantibody tests come back negative.24PubMed Central. Hereditary juvenile cobalamin deficiency caused by mutations in the intrinsic factor gene
This condition typically presents in childhood or adolescence and should be suspected in a young person with B12 deficiency who lacks the autoantibodies associated with classical pernicious anemia. Genetic testing can confirm the diagnosis. It is vanishingly uncommon compared to autoimmune pernicious anemia, but it is worth knowing about because the treatment (lifelong B12 supplementation) is identical, and a missed diagnosis in a child can lead to irreversible neurological damage.